Cancer therapeutics and orphan drugs are no longer niche areas. Specialty drugs are now a significant portion of the ...

Patent expirations are increasingly concentrated in specialty, with >$43B in 2026 brand sales exposed and meaningful ...

As therapeutic candidates advance toward commercialization, scientific achievement is no longer viewed purely as an expense tied to research and development but rather as something that can be ...

As drug candidates advance closer to commercialization, scientific progress is no longer viewed solely as research expenditure but increasingly as a measurable financial asset. This shift is being ...

Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, is pleased to announce its participation in the AACR Annual Meeting 2026, taking place April 19 ...

Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight The follicular lymphoma clinical trial analysis report delivers important insights into ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

LONDON, Feb 13 (Reuters) - Sanofi's incoming CEO, 65-year-old Belén Garijo, faces a major ⁠task ⁠to win over investors, accelerate the French company's stalled drug ⁠development pipeline and navigate ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...

This deal falls into the wider pipeline restocking trend in pharma, as companies look to protect their revenue amid looming patent expirations.

Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule ...

Advances in cancer research have led to an increasing number and variety of cancer therapies in the development pipeline, but there are concerns that traditional processes for drug development, ...